Manager Customer Service

Resume

Jeffrey W. H. Watthey

**** ********** ****

Frederick, MD 21703

Tel: 301-***-****

abhekn@r.postjobfree.com

EXPERIENCE AND EDUCATION

**** ** **** (Current Employment): Tutor, Frederick Community College, Frederick, MD

21702.

Providing tuition in chemistry to undergraduate students.

2010 (Current Employment): Associate Director, Operations, AuroIN, LLC, 4539

Metropolitan Ct., Frederick, MD 21704.

Sole representative of AuroIN (an Indian Company) in the US. Providing press releases, web

page text, and text for announcements and other communications in addition to customer service

and sales support. AuroIN’s business is search engine optimization, which involves improving

the performance of clients’ websites.

2010 (Current Employment): Adjunct Instructor, Department of Chemistry, Shepherd

University, Shepherdstown, WV 25443.

Responsible for providing undergraduate instruction in chemistry (laboratory sessions).

2009: Lecturer, Department of Chemistry, Rockville Campus, Montgomery College, 51

Mannakee Street, Rockville, MD 20850.

Adjunct faculty position. Responsible for providing undergraduate instruction in chemistry,

including laboratory sessions. Tutoring also provided.

2001 to 2008: Avalon Pharmaceuticals, 20358 Seneca Meadows Parkway, Germantown, MD

20876.

Positions of increasing responsibility, finally Associate Director, Chemistry.

Avalon Pharmaceuticals became a subsidiary of Clinical Data, Inc. (http://www.clda.com) and was

later dissolved. Clinical Data, Inc. retained the intellectual property.

Successful management of a group of synthetic medicinal and analytical chemists collaborating

with molecular biologists, biochemists, and pharmacologists to discover gene transcription

modulators functioning as anticancer agents. The analytical group employed NMR, high

resolution MS, GC, and GCMS. Also managed a 5 FTE synthesis collaboration with Asinex in

Moscow, Russia.

A clinical candidate was defined - AVN316, selected as the beta-catenin pathway project

development candidate. Metabolic stability and drug metabolism studied were pursued by the

analytical group. Further development is being pursued by Clinical Data, Inc.

Three World Patent Applications were filed.

Also responsible for chemistry computer systems and databases, computational chemistry,

compound acquisition, and Chemistry computer systems. This included the CambridgeSoft

ChemOffice registration system (a web-based registration system using Oracle for storage and

manipulation of alphanumeric data), the CambridgeSoft ENotebook and Inventory systems, and

ChemFinder PC-based databases. Leadscope, a repository for structures of all compounds in the

Avalon collection and all test data, was used for structure/activity studies, cluster analysis, etc.

Participated in business development activities related to establishing collaborative research

agreements as well as compound acquisition.

1997 to 2001: ChemRx Tucson, 9040 S. Rita Road #2338, Tucson, AZ 85747.

Positions of increasing responsibility, finally Director, ChemRx Computational Chemistry.

ChemRx was a Discovery Partners International Company. Discovery Partners has since merged

with Infinity Pharmaceuticals, which is the name of the new organization (www.infi.com)

Originally, Director, Computational Chemistry and Informatics, SIDDCO (Systems Integration

Drug Discovery Company), 9040 S. Rita Road #2338, Tucson, AZ 85747

SIDDCO was acquired by Discovery Partners International in January 2001, and became part of

the ChemRx organization.

Computational chemistry activities focused on combinatorial library design and diversity

assessment studies.

From 1993 to 1997: Coordinator, Starks C. P., (Division of Starks Associates, Inc.), 11428

Rockville Pike, Suite 309, Rockville, MD 20852

Responsible for the procurement of compounds for evaluation in the National Cancer Institute's

anticancer and AIDS antiviral drug discovery program, and facilitating drug development by

interaction with representatives of pharmaceutical companies and academic scientists conducting

research in medicinal or synthetic chemistry in the United States and the Far East, and with NCI

staff. This required familiarity with screening protocols, criteria for compound advancement, the

status of important drugs, either marketed or under development, biological test data on

compounds submitted by the suppliers, the suppliers' research programs, structure-activity

relationships, confidentiality agreements, and patenting strategy. Responsible for components of

original and renewal government contract applications.

From 1992 to 1993: Adjunct Instructor, Union County College, 1033 Springfield Avenue,

Cranford, NJ 07016

Responsible for providing undergraduate instruction in organic chemistry and biochemistry,

including laboratory sessions.

From 1964 to 1993: Ciba Pharmaceuticals (Division of Ciba-Geigy Corporation), 556 Morris

Avenue, Summit, NJ 07901.

Positions of increasing responsibility, finally Manager, Chemical Database Support, Research

Department.

Ciba is now part of Novartis Corporation.

Originally, Research Chemist, Organic Chemistry Department, Geigy Pharmaceuticals (Division

of Geigy Chemical Corporation), Ardsley, NY. Geigy subsequently merged with the Ciba

Corporation to become Ciba-Geigy.

Responsible for the Division's structure and reaction databases (registration, systems

enhancement, and training). Leader of a group responsible for setting goals in the area of 3D

database creation and utilization.

From 1986 to 1988: Manager, Drug Discovery Operations. Responsibilities included the

preparation and monitoring of capital and operating budgets for the Drug Discovery Division and

the overseeing of academic grant disbursements; the operation of the Chemistry Research

stockroom and database and the establishment and operation of the research sample registration,

storage, and dispensing facility which included a computer-based inventory system; the

transmission of research samples to and the requisition and accessioning of such samples from

the Basel, Switzerland facilities of Ciba-Geigy and other outside organizations; recruiting and

hiring of non-supervisory Chemistry Research personnel; safety matters relating to the

Chemistry Research Department, and USAN applications.

Conducted research in medicinal chemistry with an emphasis on cardiovascular projects

(angiotensin-converting enzyme inhibitors).

From 1983 to 1986: Manager, Chemistry Research Operations. Administrative responsibilities

similar to those described above. Established the Chemistry Research stockroom and database.

Conducted research in medicinal chemistry with an emphasis on cardiovascular and CNS

projects. Responsible for the design and synthesis of libenzapril, an angiotensin-converting

enzyme inhibitor that reached phase III of clinical trials.

From 1972 to 1983: Senior Staff Scientist, Chemistry Research. Conducted research in

medicinal chemistry. Areas of interest included the synthesis of potential antihypertensives,

neuroleptics, and antidepressants. Responsible for the design and synthesis of benazepril

hydrochloride, an angiotensin-converting enzyme inhibitor marketed as an antihypertensive in

this country (Lotensin) and in several others (Cibacen), in combination with hydrochlorothiazide

as Lotensin HCT, with amlodipine as Lotrel, and as Fortekor for the treatment of heart failure in

dogs. Also responsible for the design and synthesis of an antidepressant agent which

successfully underwent 90-day toxicity studies in two species.

From 1964 to 1971: Research Chemist, Organic Chemistry Department, Geigy Pharmaceuticals

(Division of Geigy Chemical Corporation), Ardsley, NY. Conducted research in medicinal

chemistry on antihypertensive agents and enzyme inhibitors.

Postdoctoral Studies (1962-1963): Department of Chemistry, University of California, Los

Angeles. Conducted research on medium ring cycloalkenes in collaboration with the late Saul

Winstein.

Postgraduate Education (1959-1962): St. Catherine's College, Oxford University, Oxford,

England. Conducted research on the synthesis of the sesquiterpene, longifolene, via an

intramolecular Diels-Alder approach, under the supervision of Professor M. C. Whiting.

Awarded the degree of D. Phil.

College Education (1956-1959): The Royal College of Science (Part of the Imperial College of

Science and Technology), London, England. Awarded the B. Sc. degree (chemistry major) with

upper 2nd class honors.

PUBLICATIONS, PATENTS, AND LECTURES

Avalon Patent Application WO/2009/36429 filed 5/2/09: Hydroxypiperidine Derivatives and

Uses Thereof, Jeffrey W. Watthey, et al.

Avalon Patent Application WO/2008/140792 filed 5/9/08: Derivatives of Fluorene, Anthracene,

Xanthene, Dibenzosuberone and Acridine, Jeffrey W. Watthey, et al.

Avalon Patent Application WO/2008/1330975 filed 4/25/08: Multi-Ring Compounds and Uses

Thereof, Jeffrey W. Watthey, et al.

Identification of Small Molecule Inhibitors of the Aurora/Centrosome Pathway. I. Lonskaya, J.

Watthey, et al., poster presentation given by I. Lonskaya at the AACR Annual Meeting, San

Diego, CA, Apr 12-16, 2008.

An Evaluation of Pharmacodynamic Markers for the Identification of Novel Therapeutic Agents

that Modulate the Wnt Signaling Pathway. P. Adiseshaiah, J. Watthey, et al., poster presentation

given by P. Adiseshaiah at the AACR Annual Meeting, San Diego, CA, Apr 12-16, 2008.

Avalon Compound Profiling Toolkit: Use of Gene Transcription Biomarker Signatures for Drug

Discovery. S. Katz, J. Watthey, et al., poster presentation given by S. Katz at the AACR Annual

Meeting, San Diego, CA, Apr 12-16, 2008.

In vitro Characterization of Wnt/Beta-catenin Pathway Inhibition in Multiple Myeloma Cell

Lines Using a Novel Class of Small Molecules. J. Strovel, J. Watthey, et al., poster presentation

given by J. Strovel at the ASH 49th Annual Meeting, Atlanta, GA, Dec 7-11, 2007.

Compounds selected and optimized from a biomarker based beta-catenin pathway screen

decrease beta-catenin protein levels in xenograft tumors, induce a gene expression signature

consistent with inhibition of beta-catenin activity, and exhibit antitumor growth properties. Z.

Weaver, J. Watthey, et al., poster presentation given by Z. Weaver at the AACR-NCI-EORTC

2007 International Conference, San Francisco, CA, Oct 22-26, 2007.

LC-363: Optimization and in vitro Characterization of a Novel Series of Small Molecule

Inhibitors of the Wnt/Beta-catenin Signaling Pathway. I. Lonskaya, J. Watthey, et al., poster

presentation given by I. Lonskaya at the AACR-NCI-EORTC 2007 International Conference,

San Francisco, CA, Oct 22-26, 2007.

A biomarker based high throughput screen identifies small molecular weight modulators of the

beta-catenin pathway. D. Soppet, J. Watthey, et al., poster presentation given by D. Soppet at the

AACR-NCI-EORTC 2007 International Conference, San Francisco, CA, Oct 22-26, 2007.

Biomarker-driven Drug Discovery: Identification and Characterization of small molecule

inhibitors against beta-catenin and Aurora kinase. P. R. Young, J. Watthey, et al., poster

presentation given by P. R. Young at the AACR Annual Meeting, Washington, DC, April 2006.

Avalon Patent Application WO/2007/098086 (Aurora/Centrosome pathway compounds) filed

2/17/06: Hydroxypiperidine Derivatives and Uses Thereof, Jeffrey W. Watthey, et al.

Comprehensive Mechanism-of-Action Based Clustering of Anti-Cancer Drugs by Large-Scale

Transcriptional Profiling. D. Bol, J. Watthey, et al., poster presentation given by D. Bol at the

AACR Japanese Cancer Association Joint Conference on Advances in Cancer Research in

Hawaii, January 2004.

Forward Chemical Genomics: Selection of Preclinical Lead Compounds Using

Transcriptional Profiling in Every Stage of the Drug Discovery Process. R. Ebner, J.

Watthey, et al., Presentation given by R. Ebner at the Second International Symposium on

Signal Transduction Modulators in Cancer Therapy, Amsterdam. October 2003.

HITS: A High-throughput Integrated Transcriptional Screen for Identifying Potential

Therapeutic Agents. D. R. Soppet, J. Watthey, et al., Presentation given by D. R. Soppet at the

American Association for Cancer Research 94th Annual Meeting, Washington DC, July 2003.

Comprehensive Mechanism-of-Action Based Clustering of Anti-cancer Drugs by Large-scale

Transcriptional Profiling. P. Young, J. Watthey, et al., Presentation given by P. Young at the

American Association for Cancer Research 94th Annual Meeting, Washington DC, July 2003.

Forward Chemical Genomics – A Novel Drug Discovery Process Based on Genomic

Technology. S. Pikul, J. Watthey, et al, Presentation given by S. Pikul at MipTec 2003, Basel

Switzerland, May 2003.

The National Cancer Institute's Drug Discovery Program. Presentation given at the 3rd

International Symposium for Chinese Organic Chemists, Taipei, Taiwan, Republic of China,

November 10-13, 1994.

The Pharmaceutical Industry. A chapter in the 9th edition of Riegel's Handbook of Industrial

Chemistry, J. A. Kent, editor. Van Nostrand Reinhold, New York, NY; 1992.

Error Detection and Correction in a Corporate Structural Database. Presentation given at the

MDL Software Users' Group Meeting, San Francisco, CA, April 9-12, 1991.

U. S. Patents 4,824,868 (1989), 4,692,469 (1987), and 4,588,746 (1986): Propylamine

Derivatives (Antidepressant Agents). Broad foreign coverage has been secured.

U. S. Patents 4,575,503 and 4,600,534 (1986), 4,473,575 (1984), and 4,410,520 (1983): 3-

Amino-[1]-benzazepine-2-one-1-alkanoic acids (Angiotensin Converting Enzyme Inhibitors).

Broad foreign coverage has been secured.

U. S. Patent 4,537,885 (1985) and 4,470,988 (1984): Benzazocinone and Benzazoninone

Derivatives and their Pharmaceutical Use (Angiotensin Converting Enzyme Inhibitors). Broad

foreign coverage has been secured.

U. S. Patent 4,515,792 (1985): Tetracyclic Heterocycles for Antidepressant Compositions.

Angiotensin Converting Enzyme Inhibitors: Structure-Activity Profile of 1-Benzazepin-2-one

Derivatives. J. Med. Chem., 1985, 28, 1603.

Synthesis and Biological Properties of (Carboxyalkyl)amino Substituted Bicyclic Lactam

Inhibitors of Angiotensin Converting Enzyme. J. Med. Chem., 1985, 28, 1511.

Dibenzodiazepines and other Tricyclic Diazepine Systems (Chapter 1 of Azepines; Volume 43,

Part 2 of the Weissberger/Taylor series, "The Chemistry of Heterocyclic Compounds"). John

Wiley & Sons, New York, NY; 1984, pp 1-717.

Bicyclic Lactam Inhibitors of Angiotensin Converting Enzyme. J. Med. Chem., 1984, 27, 816.

Bicyclic Lactam Inhibitors of Angiotensin Converting Enzyme. ACS, 186th National Meeting,

Washington, DC. August 28 - September 2, 1983. Abstract MEDI-93.

Synthesis and Biological Profile of Thiophene Ring Analogs of Mianserin. J. Med. Chem., 1983,

26, 1116.

Application of Regioselective Thiophene Lithiation to the Synthesis of Thiophene Analogs of

Xanthones and Thioxanthones. J. Org. Chem., 1982, 47, 1755.

Inferences on the Nature of the Apical Sodium Entry Site in Frog Skin Epithelium (with D. J.

Benos). J. Pharm. Exp. Therap., 1981, 219, 481.

Synthesis and Diuretic Profile of 3-(3-Amino-1,2,4-oxadiazol-5-yl)-5-chloro-2,6-pyrazine-

diamine, an Amiloride-Type Diuretic. J. Med. Chem., 1980, 23, 690.

Synthesis, Antifertility and Hypocholesteremic Activity of some Bridged Isoindoline

Derivatives, ACS, 173rd National Meeting, New Orleans, LA, March 20-25, 1977. Abstract

MEDI-12.

The Synthesis of a Tetracyclic Ajmalicine Analog. J. Org. Chem., 1976, 41, 3714.

A Convenient Preparation of 1-Aroylpiperazines. Org. Prep. Proced. Int., 1976, 8, 85.

Studies on the Synthesis of Benzo[b]quinolizinium Salts. J. Org. Chem., 1973, 38, 4170.

U. S. Patents 3,712,946 (1973) and 3,565,899 (1971): Benzo[b]quinolizinium Compounds

(Hypotensive, CNS, and Antipyretic Agents). Also issued in several foreign countries.

Model Building (part of a symposium on "The Enzyme as a Model for the Pharmacological

Receptor Site" - with F. H. Clarke), ACS, 13th National Medicinal Chemistry Symposium, Iowa

City, IA, June 18-22, 1972.

U. S. Patents 3,621,098 (1971) and 3,484,443 (1969): Hydroxy- and Methoxyhexahydro-

benzo[b]quinolizines (Cardiovascular and CNS Agents). Also issued in several foreign

countries.

Dutch Patent 67 17,413 (1967): Substituted Benzylpyridinium Compounds (Hypotensive and

Sympathomimetic Agents). Also issued in other countries.

Isolation and Valency Isomerization of cis-cis-cis-1,3,5-cyclononatriene (with D. S. Glass and S.

Winstein). Tetrahedron Letters, 1965, 377.

Isomerization of some Cyclononatrienes (with S. Winstein). J. Amer. Chem. Soc., 1963, 85,

3715.

Contact this candidate